FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255120259> ?p ?o ?g. }

• W4255120259 abstract "HomeCirculationVol. 130, No. 23Correction Free AccessCorrectionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCorrectionPDF/EPUBCorrection Originally published2 Dec 2014https://doi.org/10.1161/CIR.0000000000000142Circulation. 2014;130:e270–e271This article corrects the following2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive SummaryIn the article by January et al, “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society,” which published online March 28, 2014, and appeared in the December 2, 2014, issue of the journal (Circulation. 2014;130:2071–2104), several corrections were needed.On page 2079, in the first column, the second paragraph, the Class III: No Benefit recommendation 1 read, “The direct thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban are not recommended in patients with AF and end-stage CKD or on hemodialysis because of the lack of evidence from clinical trials regarding the balance of risks and benefits.” It has been changed to read, “The direct thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban are not recommended in patients with AF and end-stage CKD or on dialysis because of the lack of evidence from clinical trials regarding the balance of risks and benefits.”On page 2078, in Table 5, in the penultimate row, the Class III: No Benefit recommendation 1 read, “Direct thrombin dabigatran and factor Xa inhibitor rivaroxaban are not recommended in patients with AF and end-stage CKD or on hemodialysis because of a lack of evidence from clinical trials regarding the balance of risks and benefits.” It has been changed to read, “Direct thrombin dabigatran and factor Xa inhibitor rivaroxaban are not recommended in patients with AF and end-stage CKD or on dialysis because of a lack of evidence from clinical trials regarding the balance of risks and benefits.”On page 2080, in Table 7, in row 1, the entry in the fourth column “Rivaroxaban” read, “20 mg HS.” It has been changed to read, “20 mg QD with the evening meal.”On page 2080, in Table 7, in row 2, the entry in the third column “Dabigatran” read, “150 mg BID or 75 mg BID (CrCl >30 mL/min).” It has been changed to read, “150 mg BID (CrCl >30 mL/min).”On page 2080, in Table 7, in row 2, the entry in the fourth column “Rivaroxaban” read, “15 mg HS.” It has been changed to read, “15 mg QD with the evening meal.”On page 2080, in Table 7, in row 3, the entry in the fourth column “Rivaroxaban” read, “15 mg HS.” It has been changed to read, “15 mg QD with the evening meal.”On page 2080, in Table 7, the footnote list read, “…§Modeling studies suggest that dabigatran 75 mg BID might be safe for patients with CrCl 15–30 mL/min, but this has not been validated in a prospective cohort. Some countries outside the United States use 110 mg BID. ‖Dose-adjusted warfarin has been used, but observational data on safety and efficacy are conflicting…” It has been changed to read, “§Dose-adjusted warfarin has been used, but observational data on safety and efficacy are conflicting. ‖Modeling studies suggest that dabigatran 75 mg BID might be safe for patients with CrCl 15–30 mL/min, but this has not been validated in a prospective cohort. Some countries outside the United States use 110 mg BID.” Symbols in the table were adjusted accordingly.On page 2080, in Table 7, the footnote abbreviation list read, “...CrCl, creatinine clearance; HS, once daily in evening with food; and INR, international normalized ratio.” It has been changed to read, “...CrCl, creatinine clearance; FDA, Food and Drug Administration; INR, international normalized ratio; and QD, once daily.”On page 2082, in Table 9, in the first column, the last line, an asterisk (*) was inserted after “Amiodarone,” and the following was added to the footnotes, “*Multiple dosing schemes exist for the use of amiodarone.”On page 2084, in Table 11, in the second row “Dofetilide” under the “Vaughan Williams class III” heading, in the “Exclude/Use With Caution” column, “Hypomagnesemia” was added to the bulleted list.On page 2084, in Table 11, in the row “Dofetilide” row under the “Vaughan Williams class III” heading, in the “Major Pharmacokinetic Drug Interactions” column, the text read, “Metabolized by CYP3A: verapamil…”. It has been changed to read, “Primary renal elimination involving glomerular filtration and active tubular secretion: verapamil…”On page 2075, in Table 2, page 2076 in the text, and page 2090 in the Reference Section, Reference 8 was removed and replaced with references 8a and 8b.Reference 8 read,8. Agency for Healthcare Research and Quality. Research protocol: treatment of atrial fibrillation. Available at: http://effectivehealthcare.ahrq.gov/ehc/products/358/946/AtrialFibrillationTreatment_AmendedProtocol_20120530.pdf. 2012. Accessed May 23, 2014.References 8a and 8b read,8a. Al-Khatib SM, Allen Lapointe N, Chatterjee R, et al. Treatment of Atrial Fibrillation. Comparative Effectiveness Review 119. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No.13-EHC095-EF. Rockville, MD: Agency for Healthcare Research and Quality; June 2013. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/358/1559/atrial-fibrillation-report-130628.pdf. Accessed August 14, 2014.8b. Lopes RD, Crowley MJ, Shah BR, et al. Stroke Prevention in Atrial Fibrillation. Comparative Effectiveness Review No. 123. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 13-EHC113-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2013. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/352/1668/stroke-atrial-fibrillation-report-130821.pdf. Accessed August 14, 2014.These corrections have been made to the print version and to the current online version of the article, which is available at http://circ.ahajournals.org/content/130/23/2071.full. Previous Back to top Next FiguresReferencesRelatedDetailsRelated articles2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive SummaryCraig T. January, et al. Circulation. 2014;130:2071-2104 December 2, 2014Vol 130, Issue 23 Advertisement Article InformationMetrics © 2014 American Heart Association, Inc.https://doi.org/10.1161/CIR.0000000000000142 Originally publishedDecember 2, 2014 PDF download Advertisement" @default.
• W4255120259 created "2022-05-12" @default.
• W4255120259 date "2014-12-02" @default.
• W4255120259 modified "2023-09-25" @default.
• W4255120259 title "Correction" @default.
• W4255120259 doi "https://doi.org/10.1161/cir.0000000000000142" @default.
• W4255120259 hasPublicationYear "2014" @default.
• W4255120259 type Work @default.
• W4255120259 citedByCount "0" @default.
• W4255120259 crossrefType "journal-article" @default.
• W4255120259 hasBestOaLocation W42551202591 @default.
• W4255120259 hasConcept C126322002 @default.
• W4255120259 hasConcept C142724271 @default.
• W4255120259 hasConcept C164705383 @default.
• W4255120259 hasConcept C2776301958 @default.
• W4255120259 hasConcept C2776710957 @default.
• W4255120259 hasConcept C2778661090 @default.
• W4255120259 hasConcept C2778810321 @default.
• W4255120259 hasConcept C2779161974 @default.
• W4255120259 hasConcept C2780182762 @default.
• W4255120259 hasConcept C535046627 @default.
• W4255120259 hasConcept C71924100 @default.
• W4255120259 hasConceptScore W4255120259C126322002 @default.
• W4255120259 hasConceptScore W4255120259C142724271 @default.
• W4255120259 hasConceptScore W4255120259C164705383 @default.
• W4255120259 hasConceptScore W4255120259C2776301958 @default.
• W4255120259 hasConceptScore W4255120259C2776710957 @default.
• W4255120259 hasConceptScore W4255120259C2778661090 @default.
• W4255120259 hasConceptScore W4255120259C2778810321 @default.
• W4255120259 hasConceptScore W4255120259C2779161974 @default.
• W4255120259 hasConceptScore W4255120259C2780182762 @default.
• W4255120259 hasConceptScore W4255120259C535046627 @default.
• W4255120259 hasConceptScore W4255120259C71924100 @default.
• W4255120259 hasIssue "23" @default.
• W4255120259 hasLocation W42551202591 @default.
• W4255120259 hasOpenAccess W4255120259 @default.
• W4255120259 hasPrimaryLocation W42551202591 @default.
• W4255120259 hasRelatedWork W142423038 @default.
• W4255120259 hasRelatedWork W1679435851 @default.
• W4255120259 hasRelatedWork W2003634422 @default.
• W4255120259 hasRelatedWork W2028819591 @default.
• W4255120259 hasRelatedWork W2080910965 @default.
• W4255120259 hasRelatedWork W2097201002 @default.
• W4255120259 hasRelatedWork W2152207710 @default.
• W4255120259 hasRelatedWork W2990629389 @default.
• W4255120259 hasRelatedWork W3370658 @default.
• W4255120259 hasRelatedWork W168870552 @default.
• W4255120259 hasVolume "130" @default.
• W4255120259 isParatext "false" @default.
• W4255120259 isRetracted "false" @default.
• W4255120259 workType "article" @default.